Результаты поиска

Cancer immunity and immunotherapy beyond COVID-19.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… Angela Santoni (Rome, Italy), Catherine Sautes-Fridman (Paris, France), Marco Cassatella (Verona, Italy) and Renato Ostuni (Milano, Italy) acted as discussants in this session. … The session was jointly organized with the Alleanza Contro il Cancro (ACC) and witnessed Paola Nisticò (Rome), Matteo Bellone (Milan), Vincenzo Bronte (Verona) and Rugero De Maria (Rome) as discussants. …

UEG Week 2017 Oral Presentations

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… Diagnosis is based on the Rome III criteria. However, combination of the Rome III criteria have a sensitivity, specificity, PPV and NPV of 65%, 100%, 100% and 76%. Current tests commonly fail to obtain an objective diagnosis. … Prague/Czech Republic 5 AZ Delta Roeselare-Menen, Menen/Belgium 6 Hepato-Gastroenterologie HK, s.r.o., Hradec Králové/Czech Republic 7 Bezmialem Vakif University, İstanbul/Turkey 8 Medical University of Vienna, Vienna/Austria 9 Presidio Columbus, Fondazione Policlinico Gemelli Università Cattolica, Rome …

ICAR 2011. Italian Conference on AIDS and Retroviruses, Florence, Italy, 27-29 March 2011. Abstracts.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… Spallanzani IRCCS, Rome, Italy; 2 Università di Bari, Bari, Italy; 3 A.O. … , homeless, immigrants) living in Rome. …

Commentary on: "Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES study." Escudier B, Porta C, Bono P, Powles T, Eisen T, Sternberg CN, Gschwend JE, De Giorgi U, Parikh O, Hawkins R, Sevin E, Négrier S, Khan S, Diaz J, Redhu S, Mehmud F, Cella D. Bernard Escudier, Institut Gustave Roussy, Villejuif; Emmanuel Sevin, Centre François Baclesse, Caen; Sylvie Négrier, Leon Berard Cancer Center, Lyon, France; Camillo Porta, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico S. Matteo, Pavia; Cora N Sternberg, San Camillo Forlanini Hospital, Rome; Ugo De Giorgi, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy; Petri Bono, Helsinki University Central Hospital, Helsinki, Finland; Thomas Powles, Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London; Tim Eisen, Cambridge University Health Partners, Cambridge; Omi Parikh, Royal Preston Hospital, Lancashire; Robert Hawkins, Christie Cancer Research UK, Manchester; Sadya Khan, Jose Diaz, and Faisal Mehmud, GlaxoSmithKline, Uxbridge, United Kingdom; Jürgen E Gschwend, Klinikum Rechts der Isar der Technischen Universität München, Munich, Germany; Suman Redhu, GlaxoSmithKline, Collegeville, PA; David Cella, Northwestern University Feinberg School of Medicine, Chicago, IL.: J Clin Oncol. 2014 May 10;32(14):1412-1418; doi: 10.1200/JCO.2013.50.8267. [Epub 2014 Mar 31].

PURPOSE: Patient-reported outcomes may help inform treatment choice in advanced/metastatic renal cell carcinoma (RCC), particularly between approved targeted therapies with similar efficacy. This double-blind crossover study evaluated patient preference for pazopanib or sunitinib and the influence of health-related quality of life (HRQoL) and safety factors on their stated preference. PATIENTS AND METHODS: Patients with metastatic renal cell carcinoma were randomly assigned to pazopanib 800mg per day for 10 weeks, a 2-week washout, and then sunitinib 50mg per day (4 weeks on, 2 weeks off, 4we

Clinical and epidemiological features of ulcerative colitis patients in Sardinia, Italy: Results from a multicenter study.

BACKGROUND: There are little data on the epidemiological and clinical features of adult patients with ulcerative colitis (UC) in the different Italian regions, mainly derived from the absence of a national registry. This prevents correct interpretation of the disease burden. AIM: To assess the main clinical and epidemiological features of adult patients diagnosed with UC in Sardinia, Italy. METHODS: We performed a multicenter, observational, cross-sectional study that included adult patients with UC enrolled in seven gastroenterology unit centers in Sardinia. Data were obtained from the pati

Совпадение в полном тексте источника
… Walter Elisei, Gastroenterology Unit, San Camillo Forlanini Hospital, Rome 00152, Italy. Manuela Marzo, Internal Medicine and Gastroenterology Department, Cardinale Panico Hospital, Tricase 73039, Italy. Federica Miculan, Department of Surgery, San Martino Hospital, Oristano 09170, Italy. … Massimo Claudio Fantini, Department of Internal Medicine, University of Rome Tor Vergata, Rome 00133, Italy. Alessandro Armuzzi, IBD Unit, Policlinico Universitario Gemelli, Rome 00168, Italy. Giammarco Mocci, Gastroenterology Unit, Brotzu Hospital, Cagliari 09121, Italy. …

Mechanisms inducing low bone density in Duchenne muscular dystrophy in mice and humans.

Patients affected by Duchenne muscular dystrophy (DMD) and dystrophic MDX mice were investigated in this study for their bone phenotype and systemic regulators of bone turnover. Micro-computed tomographic (µCT) and histomorphometric analyses showed reduced bone mass and higher osteoclast and bone resorption parameters in MDX mice compared with wild-type mice, whereas osteoblast parameters and mineral apposition rate were lower. In a panel of circulating pro-osteoclastogenic cytokines evaluated in the MDX sera, interleukin 6 (IL-6) was increased compared with wild-type mice. Likewise, DMD patie

Совпадение в полном тексте источника
… All reagents were from 2M Strumenti (Rome, Italy) and Bio Optica (Milan, Italy). … Bone mass BMD was evaluated by DXA (Hologic Discovery A in Milan and Hologic Delphi W in Rome; Hologic, Inc., Waltham, MA, USA) at the lumbar spine (L 2 –L 4 ) using the same scanning and analysis protocol in all centers. …

Progressive multifocal leukoencephalopathy during bispecific antibody therapy in multiple myeloma: from immune dysfunction to early recognition. Comment on: "Progressive multifocal leukoencephalopathy and BK virus-nephropathy with bispecific antibody therapy in multiple myeloma".

Not available.

Совпадение в полном тексте источника
… and BK virus-nephropathy with bispecific antibody therapy in multiple myeloma” Davide Facchinelli1, Livio Pagano2,3 1Hematology Unit, Department of Clinical Oncology, San Bortolo, Vicenza, Italy 2Section of Hematology, Department of Radiological and Hematological Sciences, Catholic University, Rome … , Italy 3Department of Laboratory and Hematological Sciences, Fondazione Policlinico Gemelli IRCCS, Rome, Italy Running head: PML during bispecific antibody therapy. …

Late Breaking Orals.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Abstracts from 2020 national congress of the Italian Society of Hypertension (SIIA).

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… University of Pisa, Pisa, Italy; 12 Department of Internal Medicine, Santa Maria della Misericordia General Hospital, AULSS 5 Polesana, Rovigo, Italy; 13 Department of Clinical and Experimental Sciences, University of Brescia, Brescia; 14 Department of Clinical and Molecular Medicine, University of Rome … Sapienza, Sant’Andrea Hospital, Rome, Italy; 15 Department of Geriatric and Intensive Care Medicine, Careggi Hospital and University of Florence, Florence, Italy; 16 Hospital S. …

The effect of interferon beta on quality of life in patients with multiple sclerosis: A systematic review and meta-analysis study.

Background: Multiple sclerosis (MS) is one of the most common progressive neurological disorders affecting young adults. This study aimed to perform a meta-analysis on the effect of interferon beta (IFN-β) on the quality of life (QOL) of patients with MS. Methods: Using valid keywords and searching through databases like Medlib, ScienceDirect, PubMed, etc., 10 articles published between 1999 and 2020 were collected. The inclusion criteria were developed based on clinical guidelines, focusing on studies involving adults with MS treated with IFN-β, with outcomes measuring QOL. The exclusion crit

Совпадение в полном тексте источника
… 30.4 ± 7.0 IFN B 1b Women with RRMS were randomly assigned (1:1:1) to receive subcutaneous IFN-b-1a (Rebif, Merck Serono, Geneva, Switzerland) 44 mcg 3 times a week (tiw) (group 1), subcutaneous IFN-b-1a 44 mcg tiw plus ethinyl estradiol 20 mcg and desogestrel 150 mcg (Mercilon, MSD Italia SRL, Rome … , Italy) (group 2) or subcutaneous IFN-b-1a 44 mcg tiw plus ethinyl estradiol 40 mcg and desogestrel 125 mcg (Gracial, Organon Italia S.p.A., Rome, Italy) (group 3) 1.7 CH, En, EW, HD, HP, PH, RLEP, RLPP, SF, SoF, SSF, CF 2 years MSQoL-54 RCT Simone et al. 25 41 Bari 36.8 ± 11.5 IFN-β 1a 3 CH, En, EW …

Clinical trials and the COVID-19 pandemic.

"...but why think? Why not try the experiment?..." John Hunter (1728-1793), in a letter to Edward Jenner. August 2nd, 1775. When Galen of Pe … ites, a frequent peril for the Roman armies marching on in sandals. Galen spent most of his life in Rome and was elevated to Imperial Physician at the court of Marcus Aurelius, who apparently took daily doses of Theriac, which among other components included opium. Describing the experiment to his friend Pison, Galen wrote, "as I could not possibly con …

Dietary interventions for recurrent abdominal pain in childhood.

BACKGROUND: This is an update of the original Cochrane review, last published in 2009 (Huertas-Ceballos 2009). Recurrent abdominal pain (RAP), including children with irritable bowel syndrome, is a common problem affecting between 4% and 25% of school-aged children. For the majority of such children, no organic cause for their pain can be found on physical examination or investigation. Many dietary inventions have been suggested to improve the symptoms of RAP. These may involve either excluding ingredients from the diet or adding supplements such as fibre or probiotics. OBJECTIVES: To examine…

Неделя ГЭЭ 2018 Презентации на плакате

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Esid 2014 oral presentations.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… Aiuti 1 1 San Raffaele Telethon Institute for Gene Therapy (HSR-TIGET), Milan, Italy 2 Università Vita-Salute San Raffaele, Milan, Italy 3 San Raffaele Scientific Institute, Milan, Italy 4 Ospedale Pediatrico Bambin Gesù, Rome , Italy 5 University of Rome “Tor Vergata”, Rome, Italy Study of hematopoietic … , Rome, Italy 16 Pediatric Immunology, Children's Clinical University Hospital, Riga, Latvia 17 Center of Pediatrics, Children‘s Hospital Affiliate of Vilnius University Hospital, Vilnius, Lithuania 18 Unit of Immunology and Allergology, Centre Hospitalier de Luxembourg, Luxembourg, Luxembourg 19 …

Соблюдение основанных на фактах рекомендаций по лечению костного здоровья, боли и мобильности пациентов с множественной миеломой: смешанный метод в палестинской системе здравоохранения.

Были разработаны рекомендации по оценке, регулированию и мониторингу состояния здоровья, боли и мобильности костных костей у пациентов с множественной миеломой, основанные на принципе " консенсус/доказательства " . Это исследование было проведено с целью оценки соответствия гематологов-онкологов принятым на основе консенсуса/доказательств рекомендациям в отношении оценки, регулирования и мониторинга состояния здоровья костей, боли и мобильности у пациентов с множественной миеломой, которые получали медицинскую помощь в палестинской системе здравоохранения. Рекомендации, основанные на

Совпадение в полном тексте источника
… Rome S, Noonan K, Bertolotti P, Tariman JD, Miceli T. Bone Health, Pain, and mobility: evidence-based recommendations for patients with multiple myeloma. Clin J Oncol Nurs. 2017;21(5 Suppl):47–59. doi: 10.1188/17.CJON.S5.47-59. 15. … Bilotti E, Faiman BM, Richards TA, Tariman JD, Miceli TS, Rome SI. Survivorship care guidelines for patients living with multiple myeloma: consensus statements of the International Myeloma Foundation Nurse Leadership Board. …

The prognosis of cancer patients undergoing liposomal doxorubicin-based chemotherapy: A systematic review and meta-analysis.

BackgroundIt is well known that liposome-based delivery of cytotoxic chemotherapeutics has been proposed as a putative strategy to enhance drug tolerability and efficacy compared to the conventional chemotherapy. However, its potential effect on improving prognosis remains largely unknown. The current meta-analysis is to explore the prognosis of cancer patients undergoing liposomal doxorubicin-based chemotherapy.MethodsA detailed review of English and Chinese literature was conducted up to March 21, 2020. We evaluate its possible correlations using hazard ratios (HRs) with 95% confidence inter

Совпадение в полном тексте источника
… doxorubicin 60 mg/m 2 every 21 d; doxorubicin 60 mg/m 2 every 21 d | Phase III | 20 mo | OS/PFS Harris L [ 23 ] | 2002 | USA | 108/116 | 58 (26–85)/58 (29–82) | MBC | Liposomal doxorubicin 75 mg/m 2 every 21 d; doxorubicin 75 mg/m 2 every 21 d | Phase III | 4 mo | OS/PFS Latagliata R [ 24 ] | 2008 | Rome … | 148/153 | AML | OS | 0.95 (0.72–1.26) Latagliata R | 2008 | Rome | 148/153 | AML | PFS | 1.10 (0.80–1.50) Mylonakis N | 2010 | Greece | 47/41 | NSCLC | OS | 0.92 (0.54–1.56) Mylonakis N | 2010 | Greece | 47/41 | NSCLC | PFS | 0.91 (0.59–1.42) Stathopoulos GP | 2010 | Greece | 114/115 | NSCLC | OS …

Chemotherapy-based versus chemotherapy-free stem cell mobilization (± plerixafor) in multiple myeloma patients: an Italian cost-effectiveness analysis.

Given the availability and efficacy of the mobilizing agent plerixafor in augmenting hematopoietic progenitor cell mobilization with granulocyte colony-stimulating factor (G-CSF), there is a strong case for comparing the cost-effectiveness of mobilization with G-CSF + cyclophosphamide versus G-CSF alone. This study investigated the cost and effectiveness (i.e., successful 4 million-CD34+ collection) of G-CSF alone versus high-dose cyclophosphamide (4 g/m2) + G-CSF mobilization (± on-demand plerixafor) in patients with multiple myeloma (MM) eligible for autograft in Italy. A decision tree-suppo

Совпадение в полном тексте источника
… Rome, January 2019 (in Italian). In. 32. Brouwer W, Rutten F, Koopmanschap M Costing in economic evaluations. In: Drummond M, McGuire A (eds). Economic evaluation in health care: merging theory with practice. Oxford University Press: Oxford, UK, 2001, pp 68-93. 33. … Rome: Torrinomedica S.r.l. (in Italian). In, 2019. 37. Agenzia delle Entrate. Italian Revenue Agency. National tariffs per kilometer for cars and motorbikes set by the Auto club of Italy - Art. 3, paragraph 1, of the legislative decree 2 September 1997, n. 314. …

The International Headache Congress - IHS and EHF joint congress 2021 : Virtual. 8-12 September 2021.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… Valeriani 1 1 Bambino Gesù Children's Hospital, Neuroscience, Rome, Italy; 2 IRCCS Foundation “Carlo Besta” Neurological Institute, Headache Center, Neuroalgology Department, Rome, Italy; 3 Sapienza University of Rome, Neuroscience, Rome, Italy; 4 Department of Human Neuroscience, Section of Child and … of Parma, Department of Medicine and Surgery, Headache Center, Unit of Neurology, Parma, Italy; 6 University Hospital of Rome "Tor Vergata",, Neurophysiopathology, Rome, Italy; 7 San Filippo Neri Hospital, Rome, Italy; 8 A.O.U. …

Patient-Reported Outcomes and Assessment of Quality of Life: A Focus on Multiple Myeloma.

Patients with multiple myeloma are living longer, yet the chronicity of newer treatment modalities has led to increased symptom burden and a notable effect on quality of life (QOL). The assessment of QOL and evaluation of patient-reported outcomes is an essential element to the care of this population. Patients with MM may experience unwanted side effects or disease-related symptoms that create a burden in everyday living. Subjective patient-reported information has become an important dimension to the overall care and treatment of these patients. Symptoms that negatively affect health-related

Совпадение в полном тексте источника
… These risks can increase with the use of immunomodulatory drugs, carfilzomib, or high-dose steroids ( Noonan, Rome, Faiman, & Verina, 2017 ). … Prz Menopauzalny , 14 ( 4 ), 271 – 282 . 10.5114/pm.2015.56539 26848300 PMC4733903 Noonan K. , Rome S. , Faiman B. , & Verina D ( 2017 ). Heart and lung complications: Assessment and prevention of venous thromboembolism and cardiovascular disease in patients with multiple myeloma . …

Abstracts of the 19th International Congress on Neuromuscular Diseases 7th – 11th July 2026

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… , Rome, Italy., Roma, Italy. 14 Neurology Unit, IRCCS Ospedale Policlinico San Martino, Largo R. … Vera Bril 17 1 Department of Neuroimmunology and Neuromuscular Diseases, Fondazione IRCCS, Instituto Nazionale Neurologico Carlo Besta, Milan, Italy. 2 Department of Human Neurosciences, Sapienza University of Rome, Rome, Italy. 3 Department of Neurology, Municipal Hospital, Poznań, Poland. 4 MDA ALS …